- By ICR Secretariat
- Posted Tuesday, March 16, 2021
CHMP issues positive opinion for Lilly’s COVID-19 antibodies
http://www.pharmatimes.com/news/chmp_issues_positive_opinion_for_lillys_covid-19_antibodies_1364767
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Eli Lilly’s COVID-19 antibodies bamlanivimab and etesevimab.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- Farxiga fails to achieve statistical significance in COVID-19 trial 15/04/2021 01:25 PM
- Researchers lay out hypothesis for rare side effect linked to AstraZeneca vaccine 15/04/2021 01:23 PM
- Covid in Wales: What do the stats tell us? 13/04/2021 02:10 PM
Useful Links
Contact Us
Suite 10, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org